Better Clinical Trial Safety Data Would Aid Benefit/Risk Analysis – DIA Europe Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
More work needs to be done on benefit/risk assessments before Phase II/III, industry reps say.
You may also be interested in...
FDA’s Risk/Benefit Decisions Will Be Quantified With Metric From Contractor
A recent request for proposals may signal a shift in FDA's approach to risk/benefit analysis and views on outcome measures, a move some see as bringing more transparency while also shielding the agency from criticism
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.